한빛사논문
- 조회421
Ming-Yuan Yang1, Meng-Meng Han1, Ling Tang1, Yu-Yang Bi1, Xue-Na Li2, Jee-Heon Jeong,3* Yi Wang,1* and Hu-Lin Jiang1,2*
1State Key Laboratory of Natural Medicines, Department of Pharmaceuticals, China Pharmaceutical University, Nanjing, 210009 China
2College of Pharmacy, Yanbian University, Yanji, 133002 China
3Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, 16419 South Korea
M.Y.Y., M.M.H., and L.T. contributed equally to this work.
CORRESPONDING AUTHORS: Jee-Heon Jeong, Yi Wang, Hu-Lin Jiang
Abstract
Idiopathic pulmonary fibrosis (IPF) is an age-related pulmonary interstitial disease with unclear etiology that poses a serious threat to human health. IPF interventions in clinical settings mainly involve oral medications, such as nintedanib (NIN), which exhibit limited accumulation in the lungs and neglect the epithelial micro-environment. Inhalation is an efficient route for the treatment of pulmonary diseases. However, the mucus barrier in the trachea and the extracellular matrix (ECM) barrier in the interstitium are the two main obstacles to inhaled therapeutic agent delivery. Therefore, in this study, dual barrier-penetrating inhaled liposomes (AN-TR) are constructed utilizing tris-(2-carboxyethyl)-phosphine (TCEP) and l-arginine to penetrate the mucus and ECM barriers, respectively. This approach facilitates the thorough and uniform distribution of NIN and navitoclax (ABT-263) across all five lung lobes. Furthermore, ABT-263 can remove the senescent epithelial cells in the trachea and alveoli, thereby improving the efficiency of NIN for IPF treatment. This study suggests dual barrier-penetrating inhaled liposomes as efficient noninvasive vehicles for first-line clinical medications to improve the efficacy of IPF treatment.
논문정보
- Research article
- 2024년 06월 (BRIC 등록일 2024-06-20)
- 국내(교신)+국외 연구진
- 의약학 > 약학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
